GlassScriptPhysician profile
Matthew G Shaffer
NPI 1588434658
$1,520.82
in general payments reported to CMS, 2019-2025
13 companies · $579 in 2025
The $579 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $942 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $329.08 | 2024-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.36 | 2024-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $211.67 | 2024-2025 | |
| Medtronic, INC. | $148.97 | 2024 | Vanta Adaptivestim, Intellis Adaptivestim, Accurian |
| Boston Scientific Corporation | $141.82 | 2024-2025 | Intracept |
| Abbvie INC. | $89.77 | 2024 | |
| Spinal Simplicity, LLC | $81.79 | 2025 | Ha Minuteman G3-R |
| Vertex Pharmaceuticals Incorporated | $62.89 | 2025 | |
| Pfizer INC. | $46.21 | 2024 | |
| Virtus Pharmaceuticals LLC | $29.77 | 2025 | Levorphanol Tartrate |
| Tonix Medicines, INC. | $29.45 | 2025 | Tonmya |
| Valinor Pharma, LLC | $18.32 | 2024 | Movantik |
| Mml US, INC. | $12.72 | 2025 | Reactiv8 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.